Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

641
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
641
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.4K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

601
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
601
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

748
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
748
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

799
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
799
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

676
 The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
676

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of fibrate treatment in dyslipidemia: an overview.

Current pharmaceutical design·2013
Same author

Ezetimibe therapy for dyslipidemia: an update.

Current pharmaceutical design·2013
Same author

Hydrochlorothiazide vs. chlorthalidone as the optimal diuretic for the management of hypertension.

Current pharmaceutical design·2013
Same author

PCSK9 inhibition - a novel mechanism to treat lipid disorders?

Current pharmaceutical design·2013
Same author

Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?

Current pharmaceutical design·2013
Same author

Achieving current goals in prevention and treatment of vascular disease: an update.

Current pharmaceutical design·2013

Related Experiment Video

Updated: Apr 21, 2026

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication
14:52

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Published on: December 11, 2013

11.2K

Cilostazol for intermittent claudication.

Rachel Bedenis1, Marlene Stewart, Marcus Cleanthis

  • 1Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK, EH8 9AG.

The Cochrane Database of Systematic Reviews
|November 1, 2014
PubMed
Summary
This summary is machine-generated.

Cilostazol improves walking distance for peripheral arterial disease (PAD) patients with intermittent claudication. While generally safe with mild side effects, its impact on mortality and quality of life requires further study.

More Related Videos

A Rat Model of Tibial Cortex Transverse Transport for the Treatment of Lower Limb Ischemia
09:56

A Rat Model of Tibial Cortex Transverse Transport for the Treatment of Lower Limb Ischemia

Published on: March 6, 2026

586
Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

11.6K

Related Experiment Videos

Last Updated: Apr 21, 2026

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication
14:52

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Published on: December 11, 2013

11.2K
A Rat Model of Tibial Cortex Transverse Transport for the Treatment of Lower Limb Ischemia
09:56

A Rat Model of Tibial Cortex Transverse Transport for the Treatment of Lower Limb Ischemia

Published on: March 6, 2026

586
Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

11.6K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Peripheral arterial disease (PAD) affects a significant portion of older adults, with intermittent claudication being a common symptom.
  • Intermittent claudication leads to leg pain during exercise, increasing cardiovascular mortality risk.
  • Risk factor modification, exercise, and antiplatelet therapy can improve symptoms and vascular events.

Purpose of the Study:

  • To evaluate the efficacy of cilostazol in enhancing walking distances in patients with stable intermittent claudication.
  • To assess cilostazol's effect on mortality and vascular events in PAD patients.

Main Methods:

  • A systematic review and meta-analysis of double-blind, randomized controlled trials (RCTs) comparing cilostazol with placebo or other antiplatelet agents.
  • Included 15 RCTs with 3718 participants; data analyzed using fixed-effect models.
  • Assessed initial claudication distance (ICD), absolute claudication distance (ACD), ankle-brachial index (ABI), mortality, vascular events, and quality of life.

Main Results:

  • Cilostazol significantly improved both initial and absolute claudication distances compared to placebo.
  • Ankle-brachial index was lowered with cilostazol 100 mg versus placebo.
  • Adverse effects like headache and dizziness were more frequent with cilostazol; no clear impact on mortality or major cardiovascular events was found due to limited data.

Conclusions:

  • Cilostazol is beneficial for improving walking distance in intermittent claudication due to PAD.
  • Adverse effects associated with cilostazol are generally mild and manageable.
  • Further research with larger sample sizes is needed to confirm effects on mortality, cardiovascular events, and quality of life.